Bendamustine and G-CSF support

Support Care Cancer. 2019 May;27(5):1581-1582. doi: 10.1007/s00520-018-4118-0. Epub 2018 Feb 26.

Authors

Osamu Imataki¹, Shumpei Uchida², Shigeyuki Yokokura², Makiko Uemura², Norimitsu Kadowaki²

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Kita-county, Miki-town, Kagawa, 761-0793, Japan. oima@med.kagawa-u.ac.jp.
² Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Kita-county, Miki-town, Kagawa, 761-0793, Japan.

PMID: 29484498
DOI: 10.1007/s00520-018-4118-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Bendamustine Hydrochloride / adverse effects
Chemotherapy-Induced Febrile Neutropenia / drug therapy*
Chemotherapy-Induced Febrile Neutropenia / etiology
Filgrastim / therapeutic use
Granulocyte Colony-Stimulating Factor / administration & dosage*
Humans
Lymphoma, Mantle-Cell / blood
Lymphoma, Mantle-Cell / drug therapy*
Male
Rituximab / administration & dosage
Rituximab / adverse effects

Substances

Granulocyte Colony-Stimulating Factor
Rituximab
Bendamustine Hydrochloride
Filgrastim